Search research articles
Contact Us
Filters
Showing results (301-310 of 419) with videos related to
Page
of 42
Sort By:
Journal of Hepatology
|
February 25, 2021
Activation and transcriptional profile of monocytes and CD8<sup>+</sup> T cells are altered in checkpoint inhibitor-related hepatitis
Cathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David Minor, Sandra D'Angelo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy
Adriana Hepner, Victoria G Atkinson, James Larkin, et al.
Nature Communications
|
August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Kevin Litchfield, James L Reading, Emilia L Lim, et al.
European Journal of Cancer Care
|
May 4, 2021
'This is not part of my life plan': A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosis
Emma Lidington, Carla Vlooswijk, Kate Stallard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
Christian U Blank, James Larkin, Ana M Arance, et al.
Page
of 42
Search research articles
Search
Showing results (301-310 of 419) with videos related to
Sort By:
Page
of 42
Journal of Hepatology
|
February 25, 2021
Activation and transcriptional profile of monocytes and CD8<sup>+</sup> T cells are altered in checkpoint inhibitor-related hepatitis
Cathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David Minor, Sandra D'Angelo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy
Adriana Hepner, Victoria G Atkinson, James Larkin, et al.
Nature Communications
|
August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Kevin Litchfield, James L Reading, Emilia L Lim, et al.
European Journal of Cancer Care
|
May 4, 2021
'This is not part of my life plan': A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosis
Emma Lidington, Carla Vlooswijk, Kate Stallard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
Christian U Blank, James Larkin, Ana M Arance, et al.
Page
of 42